Advertisement · 728 × 90
#
Hashtag
#PAVMZ
Advertisement · 728 × 90
Preview
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results PAVmed (NASDAQ: PAVM) reported its Q4 and full year 2024 financial results, highlighting significant progress across its subsidiaries. Lucid Diagnostics achieved record test volumes with 4,042 EsoGuard tests in Q4 (45% sequential, 84% annual increase) and $1.2 million in revenue. The company secured its first commercial insurance coverage from Highmark Blue Cross Blue Shield.Veris Health completed a private placement raising $2.4 million at a $35 million pre-money valuation, supplementing a $1.8 million NIH grant. The funds will advance their implantable physiological monitor through FDA clearance.PAVmed reported Q4 revenues from approximately 125 Veris Cancer Care Platform patients. Operating expenses were $5.2 million, including $0.7 million in stock-based compensation. The company achieved GAAP net income of $1.3 million ($0.12 per diluted share), with non-GAAP adjusted loss of $0.7 million. Cash position stood at $1.2 million, with pro forma cash of $3.6 million including Q1 2025 private placement.

#PAVM #LUCD #PAVMZ PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/PAVM/pa-vmed-provid...

0 0 0 0
Preview
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Lucid Diagnostics (NASDAQ: LUCD) reported strong Q4 2024 performance with record 4,042 EsoGuard tests processed, representing a 45% sequential and 84% annual increase. The company recognized $1.2 million in EsoGuard revenue for Q4 2024.Key achievements include securing over 20 new cash-pay concierge medicine contracts, obtaining first positive commercial insurance coverage from Highmark Blue Cross Blue Shield, and first agreement under state biomarker legislation with BCBS Rhode Island. The company completed a $22 million convertible debt refinancing and $15.3 million common stock financing, extending cash runway.Financial highlights show Q4 2024 operating expenses of $13.6 million, including $1.2 million in stock-based compensation. GAAP net loss was $11.5 million or $(0.20) per share. Cash position stood at $22.4 million as of December 31, 2024, with pro forma cash of approximately $36.9 million including Q1 2025 financing.

#LUCD #PAVM #PAVMZ Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/LUCD/lucid-diagnost...

0 0 0 0

#LUCD #PAVM #PAVMZ PAVmed Provides Business Update and Third Quarter 2024 Financial Results

www.stocktitan.net/news/LUCD/pa-vmed-provid...

0 0 0 0